AH Bio Fund IV, L.P.
SEC Form 4 insider trading activity
AH Bio Fund IV, L.P. has filed 1 SEC Form 4 filing (2 transaction rows) across 1 company, with disclosures dating back to 2026. 1 of those filings fall inside the rolling window. Most recent filing: Aug 11, 2026.
On the most recent filing, AH Bio Fund IV, L.P. is listed as 10% Owner at Braveheart Bio, Inc. Inside the rolling window, AH Bio Fund IV, L.P. reported 1 open-market purchase totaling $19.8M in BRVE and no open-market sales.
Companies traded
Other insiders at BRVE
Insider Buying
$19.8M
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has AH Bio Fund IV, L.P. made?
AH Bio Fund IV, L.P. has filed 1 SEC Form 4 filing (2 transaction rows) across 1 company since 2026.
Which companies does AH Bio Fund IV, L.P. trade?
AH Bio Fund IV, L.P. has filed SEC Form 4 disclosures for 1 company, including BRVE.
When was AH Bio Fund IV, L.P.'s most recent SEC Form 4 filing?
AH Bio Fund IV, L.P.'s most recent SEC Form 4 filing on Tracefour is dated Aug 11, 2026.
What is AH Bio Fund IV, L.P.'s total buy and sell value in the current window?
Inside the rolling retention window, AH Bio Fund IV, L.P. bought $19.8M and sold $0 based on SEC Form 4 filings.
What was AH Bio Fund IV, L.P.'s largest disclosed transaction?
The largest disclosed transaction in the current window is a purchase of 1,100,000 BRVE shares on 2026-08-07, worth $19.8M, per SEC Form 4 filings.